STAGE IV LARYNGEAL CANCER AJCC V8
Clinical trials for STAGE IV LARYNGEAL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LARYNGEAL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV LARYNGEAL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study compares three different drug combinations for people with advanced head and neck cancer that has spread or come back, and has stopped responding to immunotherapy. About 430 adults will receive either standard chemotherapy plus cetuximab, chemotherapy plus bevacizumab,…
Matched conditions: STAGE IV LARYNGEAL CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Matched conditions: STAGE IV LARYNGEAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Radiation boost may improve immunotherapy for advanced head and neck cancer
Disease control OngoingThis study compares two treatments for head and neck cancer that has spread to other parts of the body. All participants receive immunotherapy (pembrolizumab) plus chemotherapy, then half also get targeted radiation. The goal is to see if adding radiation helps people live longer…
Matched conditions: STAGE IV LARYNGEAL CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Promising combo targets Hard-to-Treat head and neck cancer
Disease control OngoingThis study tests a combination of an immunotherapy drug (cemiplimab) and two low-dose chemotherapy drugs (paclitaxel and carboplatin) in people with head and neck cancer that has returned or spread. The goal is to see if this mix can shrink tumors better than standard treatments.…
Matched conditions: STAGE IV LARYNGEAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC